AMT could stop ulceration

Article

Amniotic membrane transplantation (AMT) may stop corneal ulceration and promote epithelialization, according to an investigation.

Amniotic membrane transplantation (AMT) may stop corneal ulceration and promote epithelialization, according to an investigation.

Dr Stanislav A. Iakimenko et al., Department of Eye Burns, Ophthalmic Plastic Surgery, Keratoplasty and Keratoprosthesis, State Institution,The Filatov Institute of Eye Diseases and Tissue Therapy of the NAMS of Ukraine, Ukraine, analysed the results of 55 AMTs in 53 eyes of 53 patients.

All patients had corneal ulceration and limbal deficiency 180-360° of the limbus after grade 4-6 chemical and thermal injuries was performed. The preoperative visual acuity (VA) was

The findings showed that corneal ulceration was prevented in 98.1% of cases and corneas were epithelialized in 76.3% of AMTs. Corneal defect recurred in 7.1% of successful cases and VA was ≥0.01 in 54.8% of patients after corneal epithelialization.

VA at the last follow-up visit improved on 2 or more lines on the eye chart, compared to preoperative VA in 35.7% with corneal epithelialization. VA didn’t improve in 42.9% of successful patients and it reduced by one line in 26.2% of patients.

Please visit the latest online issue of the European Journal of Ophthalmology to see the abstract.

Newsletter

Join ophthalmologists across Europe—sign up for exclusive updates and innovations in surgical techniques and clinical care.

Recent Videos
Alfredo Sadun, MD, PhD, chief of Ophthalmology at the Doheny Eye Institute, University of California Los Angeles, shared exciting new research with the Eye Care Network during the Association for Research in Vision and Ophthalmology (ARVO) meeting on the subject of Leber hereditary optic neuropathy (LHON).
At this year's Association for Research in Vision and Ophthalmology (ARVO) meeting in Salt Lake City, Utah, Nitish Mehta, MD, shared highlights from his research documenting real-world results of aflibercept 8 mg for patients with diabetic macular oedema.
ARVO 2025: Anat Loewenstein, MD, shares data from herself and her colleagues on meeting needs of patients with diabetic retinopathy
At the American Society of Cataract and Refractive Surgeons annual meeting, Sheng Lim, MD, FRCOphth discusses the benefit of endoscopic cyclophotocoagulation for patients with primary open angle glaucoma and cataracts in the CONCEPT study
A photo of Seville, Spain, with the Congress on Controversies in Ophthalmology logo superimposed on it. Image credit: ©francovolpato – stock.adobe.com; logo courtesy COPHy
Anat Loewenstein, MD, Professor and Director, Department of Ophthalmology, Tel Aviv Medical Center, discusses the Congress on Controversies in Ophthalmology (COPHy)
Anat Loewenstein, MD, speaks about the 22nd Annual Angiogenesis, Exudation, and Degeneration Meeting in February 2025 and shares her global forecast for AI-driven home OCT
Sarah M. Thomasy, DVM, PhD, DACVO, a veterinary ophthalmologist at UC Davis, talks about how her research at the Glaucoma 360 symposium
I. Paul Singh, MD, an anterior segment and glaucoma specialist, discusses the Glaucoma 360 conference, where he participated in a panel discussion on the use of artificial intelligence (AI) in glaucoma care.
Charles Wykoff, MD, PhD, discusses his Floretina ICOOR presentation topic, retinal non-perfusion in diabetic retinopathy, with David Hutton, editor of Ophthalmology Times
© 2025 MJH Life Sciences

All rights reserved.